                               SEQUENCE LISTING

<110> GENENTECH, INC. ET AL.
 
<120> BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED 
      CONDITIONS

<130> P5574R1-WO

<140>
<141>

<150> 61/883,186
<151> 2013-09-26

<150> 61/829,236
<151> 2013-05-30

<150> 61/812,678
<151> 2013-04-16

<150> 61/802,296
<151> 2013-03-15

<160> 21    

<170> PatentIn version 3.5

<210> 1
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (6)..(6)
<223> /replace="Gly"

<220>
<221> misc_feature
<222> (1)..(10)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 1
Gly Phe Thr Phe Ser Asp Ser Trp Ile His 
1               5                   10  


<210> 2
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (4)..(4)
<223> /replace="Leu"

<220>
<221> VARIANT
<222> (10)..(10)
<223> /replace="Ser"

<220>
<221> misc_feature
<222> (1)..(18)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 2
Ala Trp Ile Ser Pro Tyr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
1               5                   10                  15      


Lys Gly 
        


<210> 3
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 3
Arg His Trp Pro Gly Gly Phe Asp Tyr 
1               5                   


<210> 4
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 4
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser 
            20                  25  


<210> 5
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 5
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
1               5                   10              


<210> 6
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      polypeptide"

<400> 6
Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu Gln 
1               5                   10                  15      


Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 
            20                  25                  30          


<210> 7
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 7
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala 
1               5                   10      


<210> 8
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (5)..(5)
<223> /replace="Val"

<220>
<221> VARIANT
<222> (6)..(6)
<223> /replace="Ile"

<220>
<221> VARIANT
<222> (7)..(7)
<223> /replace="Asn"

<220>
<221> VARIANT
<222> (9)..(9)
<223> /replace="Phe"

<220>
<221> VARIANT
<222> (10)..(10)
<223> /replace="Leu"

<220>
<221> misc_feature
<222> (1)..(11)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 8
Arg Ala Ser Gln Asp Val Ser Thr Ala Val Ala 
1               5                   10      


<210> 9
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (4)..(4)
<223> /replace="Thr"

<220>
<221> VARIANT
<222> (6)..(6)
<223> /replace="Ala"

<220>
<221> misc_feature
<222> (1)..(7)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 9
Ser Ala Ser Phe Leu Tyr Ser 
1               5           


<210> 10
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (3)..(3)
<223> /replace="Gly" or "Phe" or "Ser"

<220>
<221> VARIANT
<222> (4)..(4)
<223> /replace="Tyr" or "Phe" or "Trp"

<220>
<221> VARIANT
<222> (5)..(5)
<223> /replace="Asn" or "Ala" or "Thr" or "Gly" or "Phe" or "Ile"

<220>
<221> VARIANT
<222> (6)..(6)
<223> /replace="Val" or "Pro" or "Thr" or "Ile"

<220>
<221> VARIANT
<222> (8)..(8)
<223> /replace="Trp" or "Arg" or "Pro" or "Thr"

<220>
<221> misc_feature
<222> (1)..(9)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 10
Gln Gln Tyr Leu Tyr His Pro Ala Thr 
1               5                   


<210> 11
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 11
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys 
            20              


<210> 12
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 12
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr 
1               5                   10                  15  


<210> 13
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      polypeptide"

<400> 13
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
1               5                   10                  15      


Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys 
            20                  25                  30          


<210> 14
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 14
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 
1               5                   10      


<210> 15
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 15
Gly Phe Thr Phe Ser Asp Ser Trp Ile His 
1               5                   10  


<210> 16
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 16
Ala Trp Ile Ser Pro Tyr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
1               5                   10                  15      


Lys Gly 
        


<210> 17
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 17
Arg Ala Ser Gln Asp Val Ser Thr Ala Val Ala 
1               5                   10      


<210> 18
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 18
Ser Ala Ser Phe Leu Tyr Ser 
1               5           


<210> 19
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 19
Gln Gln Tyr Leu Tyr His Pro Ala Thr 
1               5                   


<210> 20
<211> 118
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      polypeptide"

<400> 20
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ser 
            20                  25                  30          


Trp Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Trp Ile Ser Pro Tyr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg His Trp Pro Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ala 
        115             


<210> 21
<211> 108
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      polypeptide"

<400> 21
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Ser Thr Ala 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Leu Tyr His Pro Ala 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 
            100                 105             


